Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. - Wikidata - awgldk - TriplyDB

Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.

Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37958283

about

Pharmacology and Clinical Drug Candidates in Redox Medicine Exploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular Disease Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review.Allopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials.The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans.Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options Comorbidities in patients with crystal diseases and hyperuricemia.Global metabolomic profiling of acute myocarditis caused by Trypanosoma cruzi infection The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality Endothelial progenitor cells enter the aging arena Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease.Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data.Role of Community Pharmacies for the Detection of Potentially Inappropriate Xanthine Oxidase Inhibitor Prescriptions Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis.Xanthine oxidase and cardiovascular risk in obese children.Oxidative stress and early atherosclerosis: novel antioxidant treatment.CVD and Oxidative Stress.Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis.Impact of allopurinol on risk of myocardial infarction.The hypoxanthine-xanthine oxidase axis is not involved in the initial phase of clinical transplantation-related ischemia-reperfusion injury.Xanthine oxidase inhibitors in ischaemic heart disease.Baseline and Change in Uric Acid Concentration Over Time Are Associated With Incident Hypertension in Large Korean Cohort.Uric Acid for Cardiovascular Risk: Dr. Jekyll or Mr. Hide?Extracellular but not cytosolic superoxide dismutase protects against oxidant-mediated endothelial dysfunction Febuxostat (Feburic tablet) in the management of hyperuricemia in a general practice cohort of Japanese patients with a high prevalence of cardiovascular problems.Acute gouty arthritis complicated with acute ST elevation myocardial infarction is independently associated with short- and long-term adverse non-fatal cardiac events.Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities.Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial.Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.Cardiac and renal protective effects of urate-lowering therapy.Redox regulation of epidermal growth factor receptor signaling during the development of pulmonary hypertension.Effect of Xanthine Oxidase Inhibition on Arterial Stiffness in Patients With Chronic Heart Failure.A meta-analysis of the efficacy of allopurinol in reducing the incidence of myocardial infarction following coronary artery bypass grafting.Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease Inappropriate prescription of allopurinol and febuxostat and risk of adverse events in the elderly: results from the REPOSI registry

P2860

Q26785525-F33C7B0A-D5CE-4447-97A0-ECF890034B6A Q26801173-3912360A-B5BE-4697-8373-844D1FD9CCC7 Q30234756-7DCFCE55-9429-4CBA-949B-339F8063E2CC Q30248398-7AB1BD51-8F7D-4606-8EE5-1094310FC476 Q33838927-0F39A646-CCD6-43A1-BC36-33698205FA3C Q33862472-3A90C614-1592-43EC-B8C6-EE22C128237F Q33864537-C95B6A50-8A61-4689-8D4A-AC1DA2F14D2B Q34157725-3506B418-1BF6-4A75-A1F4-0D9213141845 Q34549735-13421C99-52CF-4065-9776-99608506B454 Q34877729-3866750D-0C40-4AD7-911A-94C2198FAC0A Q35765879-8DE51A9D-FFE0-4BEC-B50D-E5224B8396C6 Q36177428-C5208C97-69F2-41F6-9129-F31A7BD34A96 Q36189989-D242F26A-DA31-4EDC-BCF2-D273E699875C Q36317644-EF733FF8-EA2B-4F27-9F16-4394E622AA3C Q36942867-257EE68E-0EA9-4F4C-A9E6-09CCB4221431 Q37018125-DCE2AB8B-2030-4347-B5CA-90788BC207F9 Q37625569-D191DD2E-08CF-4DE9-8752-EBBA216868B2 Q37710722-BC0071B6-694E-4018-B763-2D9B4876EA48 Q38269619-C69A8E79-FAFD-47C1-93D1-B3D7030650A4 Q38754143-1B6CC17D-6289-4DAF-B98B-26D8B9F9683C Q38968869-073B0E5C-4885-45CB-B21C-FC87EB3A12E0 Q39033643-91D1A13D-18F5-4595-8ADA-AE46F2C9FA17 Q39057251-85D5453F-4F1A-47A5-8556-2F5E58372FC5 Q39324330-B55BE542-E160-45A0-AD30-E66244257CE7 Q39456842-2B8A26E7-9CB7-4CFF-B8E2-EF34790FCC9E Q41983713-F3DBC656-034C-491B-B521-84FFCA3FBCA2 Q42270598-A01450CB-367B-43BB-B24A-1B739F69F087 Q43545502-483F1A87-9FA2-444F-92B8-8274FCCD049F Q43778043-23D23497-5028-4EA6-BA7F-0FA3D05A8175 Q46042171-6D648403-C119-41D7-BF13-35E603D88A1F Q48799743-B0757E76-DBC1-46E3-80E7-07047C80FDC2 Q49584618-16992E2C-9A3F-4EDD-A935-DCCA057B8A0F Q49616077-BE414148-210D-4C7A-A005-14FECFBF3153 Q52668831-CC8EE2F3-C02D-4D0D-9495-CB4C582D6B17 Q55176404-F7ED8286-E598-4DBB-8F6D-1F1CB80464CB Q55619193-6B6ADF46-05AB-4D36-A88C-3ABD17A3FA97 Q58129718-78D05D35-33E2-41B4-9ABA-264DEFFC2DEC Q58419002-5D3ED476-9576-49BC-9DDC-723D4C534874

P2860

Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis.

http://www.wikidata.org/entity/Q37958283

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Xanthine oxidase inhibition fo ...... atic review and meta-analysis.

@en

Xanthine oxidase inhibition fo ...... atic review and meta-analysis.

@nl

type

label

Xanthine oxidase inhibition fo ...... atic review and meta-analysis.

@en

Xanthine oxidase inhibition fo ...... atic review and meta-analysis.

@nl

prefLabel

Xanthine oxidase inhibition fo ...... atic review and meta-analysis.

@en

Xanthine oxidase inhibition fo ...... atic review and meta-analysis.

@nl

P1433

Q37958283-4839AB3E-6AF8-4E27-94A4-6ECE4DE6075D

P1476

Q37958283-13B717D6-F2E7-4562-95C9-43C7AE3050F7

P2093

Q37958283-2889CB72-620D-4869-8024-983E1143389B

Q37958283-423758A7-E362-4FFF-8A80-641031E1EF8B

Q37958283-7481EE92-1F9C-408F-B6F6-C75001BEDE75

Q37958283-7B108570-DC15-4D54-B196-C33425744958

Q37958283-A04ED6C7-2FF7-4B9C-AE98-35E5912CFA69

Q37958283-B5910B9E-6C3E-4A84-9968-9AB3A5A0199A

P2860

Q37958283-04314ABD-5B75-4ABA-ACB6-7A91B36BA86F

Q37958283-0C6B5436-176D-40C6-B8C8-AAFC30AF1021

Q37958283-0CA73D7D-AFC1-4879-85C2-AC1AFAD3E774

Q37958283-177B4F0A-0634-4236-A5E3-761CF7D43BCE

Q37958283-1CB0C84B-31B7-45E7-A242-3FDD1ADF0AF1

Q37958283-1D74224F-213D-4AE8-A452-BA08117F96CB

Q37958283-1EF01C84-862A-461F-A1C3-C1F4BC1D2B40

Q37958283-2233A60E-AFCC-4626-BD1C-A2C77D818FD4

Q37958283-2CD61EF9-B175-4004-B9B5-F1DB7BDFE8EE

Q37958283-347A10E2-C2DC-4B50-9F6D-2417A521A93A

P304

Q37958283-A6EDCA5B-7A3C-4C45-9B67-0D51C1713136

P31

Q37958283-2f6b1968-b4cf-4626-be10-e7b28bf4c788

Q37958283-742E43ED-10D1-49A8-A48E-6FB75B0C4ECC

P356

Q37958283-1E16344A-1C56-4597-8608-238DE5B2A368

P433

Q37958283-3D2DFDEF-0278-488C-9EF7-8AFD07ABA13D

P478

Q37958283-8E9B1344-D97E-43F1-A88C-B2B77F307FBA

P577

Q37958283-84CF7D08-66F9-455F-9A39-DD43970E5E9F

P5875

Q37958283-1715295F-B652-47F0-8A6E-9C6416EAB996

P698

Q37958283-92F7B927-42EB-40BE-8855-A7378F8059A3

P921

Q37958283-49FABC81-56C9-4B5D-BAF0-3DF254BFE2C6

Q37958283-4E02C6ED-6ADD-43F0-8C77-269FDA6D3A31

P356

J.1755-5922.2011.00277.X

P1433

Cardiovascular Therapeutics

P1476

Xanthine oxidase inhibition fo ...... atic review and meta-analysis.

@en

P2093

Jesse Dawson

http://www.w3.org/2001/XMLSchema#string

Kate McArthur

http://www.w3.org/2001/XMLSchema#string

Kennedy R Lees

http://www.w3.org/2001/XMLSchema#string

Matthew R Walters

http://www.w3.org/2001/XMLSchema#string

Peter Higgins

http://www.w3.org/2001/XMLSchema#string

Terrence J Quinn

http://www.w3.org/2001/XMLSchema#string

P2860

Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure

Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?

Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial

Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis.

High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid.

Role of oxidative stress in atherosclerosis.

P304

217-226

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1755-5922.2011.00277.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51813806

http://www.w3.org/2001/XMLSchema#string

P698

22099531

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease